Upgrade to SI Premium - Free Trial

Insmed (INSM) PT Lowered to $162 at Evercore ISI

May 15, 2026 6:13 AM

Evercore ISI analyst Gavin Clark-Gartner lowered the price target on Insmed (NASDAQ: INSM) to $162.00 (from $208.00) while maintaining a Outperform rating.

Categories

Analyst PT Change